From April 2022, the MHRA has been developing a pilot programme for GMP and GDP remediation supervision by eligible consultants acting as Compliance Monitors (CM) on behalf of companies that have been referred to the Inspection Action Group (IAG) following critical inspection deficiencies raised at an inspection. The CM will work with the company to deliver actions identified in a Compliance Protocol (CP), that has been agreed with the MHRA. High-level updates on progress against the CP will be communicated to the MHRA at a pre-agreed frequency by the CM.
Upon completion of the Compliance Protocol, the Compliance Monitor will communicate to the MHRA that the company is ready for inspection. The MHRA will then carry out an inspection to determine if the company can be removed from IAG oversight. The MHRA will maintain the right to carry out inspection(s) prior to the completion of the CP if considered necessary.
The anticipated benefits are that:
The MHRA Compliance Monitoring programme has screened and approved a number of Compliance Monitors based on their experience and independence.
ProPharma Group is pleased to announce that Dr David Crome has been deemed eligible by the MHRA to act as a Compliance Monitor in the MHRA’s compliance monitor programme for GMP and GDP remediation supervision activities.
Contact us to share more about your compliance needs.
April 15, 2016
The Drug Supply Chain Security Act (DSCSA), which was signed into law in November 2013, “outlines critical steps to build an electronic, interoperable system” to identify and trace prescription drugs...
January 10, 2014
In a Federal Register notice published today, the Food and Drug Administration (FDA) announced its intention to take enforcement action against misbranded or unapproved prescription products...
June 7, 2017
On Wednesday, June 7th, the FDA amended its final rule concerning humanitarian use devices (HUDs). The amendments to the regulations are being made in response to changes recently enacted into law...